Toward the Next Generation EGFR Inhibitors: An Overview of Osimertinib Resistance Mediated by EGFR Mutations in Non-Small Cell Lung Cancer

The authors focus on the acquired resistance to osimertinib caused by EGFR mutations which account for approximately 1/3 of all reported resistance mechanisms in NSCLCs.